BMY logo

Bristol-Myers Squibb Company

BMY
Healthcare|Drug Manufacturers - General|US
$62.14
-0.99 (-1.57%)
DCF Value
$239.82
Graham Number
$34.15
Cash / Share
$6.16

Analyst Consensus

Hold42 analysts
Strong Buy
0
Buy
19
Hold
21
Sell
2
Strong Sell
0
Consensus Target
$66.08
Implied Upside
+6.3%
Low Target
$41.00
High Target
$78.00

Price Target Trend

Last Month
$74.67
3 targets · +20% vs price
Last Quarter
$65.22
9 targets · +5% vs price
Last Year
$63.34
32 targets · +2% vs price
All Time
$65.31
61 targets · +5% vs price

Rating Trend

Dec 25
8 buy · 20 hold · 1 sell
Jan 26
9 buy · 18 hold · 1 sell
Feb 26
10 buy · 18 hold · 1 sell
Mar 26
10 buy · 18 hold · 1 sell
Apr 26
10 buy · 18 hold · 1 sell
May 26
10 buy · 18 hold · 1 sell
Jun 26
10 buy · 18 hold · 1 sell
Jul 26
10 buy · 18 hold · 1 sell
Aug 26
11 buy · 18 hold · 1 sell
Sep 26
10 buy · 17 hold · 1 sell
Oct 26
11 buy · 18 hold · 1 sell
Nov 26
10 buy · 17 hold · 1 sell

Recent Price Targets

DateFirmAnalystTargetPrice ThenSource
Oct 30, 2026Truist FinancialSrikripa Devarakonda$70.00(+14%)$61.39StreetInsider
Oct 26, 2026Piper Sandler$78.00(+27%)$61.48TheFly
Oct 12, 2026JefferiesAkash Tewari$76.00(+32%)$57.58TheFly
Oct 8, 2026Cantor FitzgeraldCarter Gould$53.00(-11%)$59.70TheFly
Oct 7, 2026Morgan StanleyTerence Flynn$41.00(-31%)$59.70TheFly
Oct 5, 2026Leerink Partners$59.00(-0%)$59.02TheFly
Sep 23, 2026Goldman SachsAsad Haider$63.00(+1%)$62.25StreetInsider
Sep 16, 2026Piper Sandler$82.00(+29%)$63.73TheFly
Sep 10, 2026HSBC$65.00(+1%)$64.41TheFly
Aug 5, 2026Roth Capital$75.00(+18%)$63.47TheFly
Aug 5, 2026Argus ResearchJasper Hellweg$75.00(+14%)$65.89TheFly
Aug 4, 2026RBC CapitalTrung Huynh$64.00(-1%)$64.73StreetInsider
Jul 31, 2026Cantor FitzgeraldCarter Gould$59.00(-7%)$63.67TheFly
Jul 31, 2026GuggenheimSeamus Fernandez$75.00(+16%)$64.86TheFly
Jul 31, 2026Wells Fargo$65.00(+0%)$64.86TheFly
Apr 8, 2026Cantor Fitzgerald$54.00(-9%)$59.20TheFly
Mar 6, 2026UBSMichael Yee$70.00(+17%)$59.78StreetInsider
Feb 24, 2026RBC CapitalTrung Huynh$60.00(-3%)$61.60StreetInsider
Feb 23, 2026Piper Sandler$75.00(+24%)$60.66TheFly
Feb 19, 2026Barclays$75.00(+24%)$60.30TheFly

Recent Rating Actions

FirmActionRatingDate
Morgan StanleymaintainUnderweightOct 30, 2026
Piper SandlermaintainOverweightOct 26, 2026
Wells FargomaintainEqual WeightOct 13, 2026
Cantor FitzgeraldmaintainNeutralOct 8, 2026
Morgan StanleymaintainUnderweightOct 7, 2026
Leerink PartnersdowngradeOutperform →Market PerformOct 5, 2026
Piper SandlermaintainOverweightSep 16, 2026
HSBCmaintainHoldSep 10, 2026
Argus ResearchupgradeHold →BuyAug 5, 2026
CitigroupmaintainNeutralAug 3, 2026
RBC CapitalmaintainSector PerformJul 31, 2026
JP MorganmaintainOverweightJul 31, 2026
Cantor FitzgeraldmaintainNeutralJul 31, 2026
Wells FargomaintainEqual WeightJul 31, 2026
GuggenheimmaintainBuyJul 31, 2026
Truist SecuritiesmaintainBuyJul 31, 2026
B of A SecuritiesmaintainBuyJul 10, 2026
Cantor FitzgeraldmaintainNeutralJul 6, 2026
B of A SecuritiesmaintainBuyApr 9, 2026
GuggenheimmaintainBuyApr 8, 2026
Cantor FitzgeraldmaintainNeutralApr 8, 2026
HSBCmaintainHoldMar 17, 2026
Piper SandlermaintainOverweightFeb 23, 2026
CitigroupmaintainNeutralFeb 6, 2026
Wells FargomaintainEqual WeightFeb 6, 2026

Earnings History

Next report: Feb 4, 2027 · EPS est. $1.56
Report DateEPS ActualEPS Est.Revenue ActualRevenue Est.
Oct 29, 2026$1.35$1.10$13.07B$12.72B
Jul 30, 2026$2.04$1.60$12.97B$11.74B
Apr 30, 2026$1.58$1.42$11.49B$10.93B
Feb 5, 2026$1.26$1.23$12.50B$12.28B
Oct 30, 2025$1.63$1.52$12.22B$11.85B
Jul 31, 2025$1.46$1.09$12.27B$11.44B
Apr 24, 2025$1.80$1.49$11.20B$10.70B
Feb 6, 2025$1.67$1.47$12.34B$11.57B

News

Wall Street Is Ignoring Bristol Myers Squibb's Cash Machine -- and That's an Opportunity for Income Investors

The average pharmaceutical stock yields 1.4%, while Bristol Myers Squibb yields 4%. Bristol Myers Squibb is working through a transition period as older drugs lose patent protection.

Nov 7, 2026fool.com
Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027?

Bristol Myers Squibb is an established pharmaceutical powerhouse with a high-yield dividend and a focus on expanding its portfolio through strategic oncology alliances. Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis market while diversifying into gene editing and treatments for acute pain.

Nov 7, 2026fool.com
Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AHA--Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy for Camzyos.

Nov 6, 2026businesswire.com
Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?

A blockbuster blood thinner is about to lose $1.5 billion to $2 billion in sales, and the debt pile hasn't gone away. Retirees counting on Bristol Myers Squibb's payout need to know which numbers actually matter before 2027 arrives.

Nov 6, 2026247wallst.com
3 High-Yield Healthcare Stocks to Buy With $1,000 and Hold Through Any Market

They are so much more than just dividend stocks.

Nov 6, 2026fool.com
48,234 Shares in Bristol Myers Squibb Company $BMY Acquired by Associated Banc Corp

Associated Banc Corp bought a new stake in shares of Bristol Myers Squibb Company (NYSE: BMY) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 48,234 shares of the biopharmaceutical company's stock, valued at approximately $3,010,000. A number of other institutional investors and

Nov 5, 2026defenseworld.net
3 of the Best Dividend Stocks to Own

These dividend stocks with economic moats offer durable payouts.

Nov 4, 2026youtube.com
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Nov 4, 2026zacks.com
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?

AbbVie is successfully navigating a critical transition period as newer immunology drugs offset revenue declines from legacy products. Bristol Myers Squibb offers a high-margin portfolio focused on oncology and hematology with a significantly lower valuation multiple.

Nov 2, 2026fool.com
BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?

Bristol Myers Squibb gains 3% after beating third-quarter estimates, as its Growth Portfolio and promising pipeline support revenue prospects despite generic competition.

Nov 2, 2026zacks.com
Bristol-Myers Squibb: Progress On The Bridge, But The Patent Cliffs Remain (Rating Downgrade)

Bristol-Myers Squibb is downgraded to 'Hold' as its current valuation appears optimistic ahead of looming patent cliffs. BMY's Growth Portfolio now comprises ~59% of revenues, with 8 medicines annualizing above $1 billion, partially offsetting legacy portfolio declines. DCF analysis values BMY at $61.19 per share, nearly matching the current price, highlighting limited upside even with near flat forward revenue growth.

Oct 30, 2026seekingalpha.com
BMY Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress

BMY raises its 2026 revenue outlook on strong Growth Portfolio sales, even as earnings pressure, patent expirations and drug launch challenges remain in focus.

Oct 30, 2026zacks.com
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Oct 30, 2026zacks.com
Bristol Myers Squibb Q3 Earnings Call Highlights

Bristol Myers Squibb NYSE: BMY raised its full-year 2026 outlook after reporting third-quarter revenue growth supported by its growth portfolio and continued strength in ELIQUIS, while outlining a series of clinical readouts and manufacturing investments intended to support its next generation of launches.

Oct 29, 2026marketbeat.com
Bristol Myers' Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction

Bristol Myers Squibb's Growth Portfolio of newer drugs grew 12% to $7.7 billion in the third quarter, supplying nearly all of the company's 7% revenue gain to $13.1 billion. Adjusted EPS fell 17% to $1.35, but mostly because of deal accounting, not a weaker core business.

Oct 29, 2026fool.com
BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook

Bristol Myers tops Q3 earnings and revenue estimates as Growth Portfolio sales and Eliquis demand drive growth, but higher IPRD charges prompt a cut to 2026 EPS guidance.

Oct 29, 2026zacks.com
Bristol-Myers Squibb Company (BMY) Q3 2026 Earnings Call Transcript

Bristol-Myers Squibb Company (BMY) Q3 2026 Earnings Call Transcript

Oct 29, 2026seekingalpha.com
Here's What Key Metrics Tell Us About Bristol Myers (BMY) Q3 Earnings

The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Oct 29, 2026zacks.com
Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Beat Estimates

Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.35 per share, beating the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $1.63 per share a year ago.

Oct 29, 2026zacks.com
Bristol Myers Squibb Raises Outlook as Quarterly Revenue Rises

Bristol Myers Squibb raised its full-year revenue outlook due to higher third-quarter revenue.

Oct 29, 2026wsj.com